| ID | 1239 |
| Name of the vaccine | GX-70 |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | DNA vaccine |
| Nucleic acid content | DNA |
| Age | 19 to 65 years |
| Description of the vaccine | DNA-based therapeutic vaccine. |
| Name of the manufacturer | Yonsei University |
| Name of the manufacturing country | NA |
| Year of manufacture | 2018 |
| Clinical Phase status | Clinical - Withdrawn |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Different dose levels given every 4 weeks 5 times. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For high risk factors for relapse and treatment failure. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03159975 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|